UNIGE document Scientific Article
previous document  unige:24968  next document
add to browser collection

Management of hepatitis C virus (HCV) infection in drug substitution programs

Witteck, Andrea
Hensel-Koch, Katharina
Thurnheer, Maria C
Bruggmann, Philip
Vernazza, Pietro
show hidden authors show all authors [1 - 11]
Published in Swiss medical weekly. 2011, vol. 141, w13193
Abstract In Switzerland, intravenous drug use (IDU) accounts for 80% of newly acquired hepatitis C virus (HCV) infections. Early HCV treatment has the potential to interrupt the transmission chain and reduce morbidity/mortality due to decompensated liver cirrhosis and hepatocellular carcinoma. Nevertheless, patients in drug substitution programs are often insufficiently screened and treated.
Keywords AdultAntiviral Agents/therapeutic useCross-Sectional StudiesDelayed Diagnosis/statistics & numerical dataFemaleGenotypeHIV Infections/complicationsHepacivirus/geneticsHepatitis C/complications/diagnosis/drug therapy/virologyHumansMaleMiddle AgedPatient Compliance/statistics & numerical dataRNA, Viral/bloodRetrospective StudiesSubstance Abuse Treatment Centers/statistics & numerical dataSubstance-Related Disorders/complicationsSwitzerlandTime FactorsYoung Adult
PMID: 21623473
Full text
Article (Published version) (421 Kb) - public document Free access
Research groups Etudes et traitement de l'hépatite C et B (554)
Groupe Laurent Kaiser (virologie clinique) (668)
Métastases du foie (657)
(ISO format)
WITTECK, Andrea et al. Management of hepatitis C virus (HCV) infection in drug substitution programs. In: Schweizerische medizinische Wochenschrift, 2011, vol. 141, p. w13193. doi: 10.4414/smw.2011.13193 https://archive-ouverte.unige.ch/unige:24968

483 hits



Deposited on : 2013-01-04

Export document
Format :
Citation style :